| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Access to opioids: a balance of harms
|
The Lancet Oncology,
|
|
2017
|
18 |
10 |
p. 1285
|
article
|
| 2 |
ACT IV: the final act for rindopepimut?
|
Gerstner, Elizabeth R
|
|
2017
|
18 |
10 |
p. 1294-1296
|
article
|
| 3 |
A family chronicle of love and death
|
Lucas, Catherine
|
|
2017
|
18 |
10 |
p. 1303-1304
|
article
|
| 4 |
Androgen deprivation therapy for prostate cancer
|
Das, Manjulika
|
|
2017
|
18 |
10 |
p. e567
|
article
|
| 5 |
Assessment of cancer control capacity and readiness: the role of the International Atomic Energy Agency
|
Abdel-Wahab, May
|
|
2017
|
18 |
10 |
p. e587-e594
|
article
|
| 6 |
BRAF V600E and BRAF-inactivating mutations in NSCLC
|
Rosell, Rafael
|
|
2017
|
18 |
10 |
p. 1286-1287
|
article
|
| 7 |
Cancer in Peru: a detailed examination
|
Coburn, Cassandra
|
|
2017
|
18 |
10 |
p. 1300-1301
|
article
|
| 8 |
Cancer patterns, trends, and transitions in Peru: a regional perspective
|
Piñeros, Marion
|
|
2017
|
18 |
10 |
p. e573-e586
|
article
|
| 9 |
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
|
Dimopoulos, Meletios A
|
|
2017
|
18 |
10 |
p. 1327-1337
|
article
|
| 10 |
Carfilzomib versus bortezomib: no longer an ENDEAVOR
|
van de Donk, Niels WCJ
|
|
2017
|
18 |
10 |
p. 1288-1290
|
article
|
| 11 |
Correction to Lancet Oncol 2017; 18: 1327–37
|
|
|
2017
|
18 |
10 |
p. e562
|
article
|
| 12 |
Correction to Lancet Oncol 2017; 18: 1338–47
|
|
|
2017
|
18 |
10 |
p. e562
|
article
|
| 13 |
Correction to Lancet Oncol 2017; 18: e564
|
|
|
2017
|
18 |
10 |
p. e562
|
article
|
| 14 |
Dabrafenib plus trametinib in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
|
Planchard, David
|
|
2017
|
18 |
10 |
p. 1307-1316
|
article
|
| 15 |
Defeating anaemia in myelodysplastic syndromes: another step forward
|
Santini, Valeria
|
|
2017
|
18 |
10 |
p. 1290-1292
|
article
|
| 16 |
Discontinuation of melanoma combination immunotherapy
|
Baker, Holly
|
|
2017
|
18 |
10 |
p. e565
|
article
|
| 17 |
E-cigarette use in young people in the UK
|
Venkatesan, Priya
|
|
2017
|
18 |
10 |
p. e571
|
article
|
| 18 |
Edinburgh Festival Fringe Roundup
|
Murray, Andrew Hunter
|
|
2017
|
18 |
10 |
p. 1305-1306
|
article
|
| 19 |
Eribulin: an effective therapeutic option in liposarcoma
|
Das, Manjulika
|
|
2017
|
18 |
10 |
p. e569
|
article
|
| 20 |
ESMO 2017 Congress
|
Gourd, Katherine
|
|
2017
|
18 |
10 |
p. 1302
|
article
|
| 21 |
Finding gold in tumour immunotherapy
|
Kaufman, Howard L
|
|
2017
|
18 |
10 |
p. e561
|
article
|
| 22 |
GeDDiS: insight into frontline therapy in soft tissue sarcoma
|
Tap, William D
|
|
2017
|
18 |
10 |
p. 1297-1299
|
article
|
| 23 |
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
|
Seddon, Beatrice
|
|
2017
|
18 |
10 |
p. 1397-1410
|
article
|
| 24 |
Growing Up with Cancer
|
Gourd, Elizabeth
|
|
2017
|
18 |
10 |
p. 1304-1305
|
article
|
| 25 |
Guadecitabine: a new therapeutic option for acute myeloid leukaemia?
|
Ferrara, Felicetto
|
|
2017
|
18 |
10 |
p. 1287-1288
|
article
|
| 26 |
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
|
Kantarjian, Hagop M
|
|
2017
|
18 |
10 |
p. 1317-1326
|
article
|
| 27 |
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|
Pavel, Marianne E
|
|
2017
|
18 |
10 |
p. 1411-1422
|
article
|
| 28 |
Immune response boosted in metastatic colorectal cancer
|
Gourd, Elizabeth
|
|
2017
|
18 |
10 |
p. e572
|
article
|
| 29 |
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
|
Kim, Sung-Bae
|
|
2017
|
18 |
10 |
p. 1360-1372
|
article
|
| 30 |
Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
|
Mitin, Timur
|
|
2017
|
18 |
10 |
p. e554
|
article
|
| 31 |
Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
|
Zeng, Haiyan
|
|
2017
|
18 |
10 |
p. e553
|
article
|
| 32 |
Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
|
Eze, Chukwuka
|
|
2017
|
18 |
10 |
p. e555
|
article
|
| 33 |
Is it time to convert the frequency of radiotherapy in small-cell lung cancer? – Authors' reply
|
Faivre-Finn, Corinne
|
|
2017
|
18 |
10 |
p. e556
|
article
|
| 34 |
Labetuzumab govitecan in metastatic colorectal cancer
|
Das, Manjulika
|
|
2017
|
18 |
10 |
p. e563
|
article
|
| 35 |
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
|
Platzbecker, Uwe
|
|
2017
|
18 |
10 |
p. 1338-1347
|
article
|
| 36 |
Maintaining quality of life for patients with neuroendocrine tumours
|
Walter, Thomas
|
|
2017
|
18 |
10 |
p. 1299-1300
|
article
|
| 37 |
miR-16: expanding the range of molecular targets in mesothelioma
|
Fennell, Dean
|
|
2017
|
18 |
10 |
p. 1296-1297
|
article
|
| 38 |
Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study
|
Sekhar, Hema
|
|
2017
|
18 |
10 |
p. 1348-1359
|
article
|
| 39 |
Nodal status and survival in anal cancer
|
Perez, Rodrigo Oliva
|
|
2017
|
18 |
10 |
p. 1292-1293
|
article
|
| 40 |
Obstructive sleep apnoea as a presenting manifestation of non-Hodgkin lymphoma in a child
|
Ganesan, Anusha-Preethi
|
|
2017
|
18 |
10 |
p. e618
|
article
|
| 41 |
Pazopanib for advanced liposarcoma
|
Gilbert, Judith A
|
|
2017
|
18 |
10 |
p. e564
|
article
|
| 42 |
Pharma funding and breast cancer advocacy: the secret war
|
Lokody, Isabel
|
|
2017
|
18 |
10 |
p. 1303
|
article
|
| 43 |
Resource-stratified implementation of a community-based breast cancer management programme in Peru
|
Duggan, Catherine
|
|
2017
|
18 |
10 |
p. e607-e617
|
article
|
| 44 |
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|
Weller, Michael
|
|
2017
|
18 |
10 |
p. 1373-1385
|
article
|
| 45 |
Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma
|
Tanimoto, Tetsuya
|
|
2017
|
18 |
10 |
p. e557
|
article
|
| 46 |
Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma – Authors' reply
|
Chiappella, Annalisa
|
|
2017
|
18 |
10 |
p. e558
|
article
|
| 47 |
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
|
van Zandwijk, Nico
|
|
2017
|
18 |
10 |
p. 1386-1396
|
article
|
| 48 |
SRS versus WBRT for resected brain metastases
|
Yue, Jinbo
|
|
2017
|
18 |
10 |
p. e559
|
article
|
| 49 |
SRS versus WBRT for resected brain metastases – Authors' reply
|
Roberge, David
|
|
2017
|
18 |
10 |
p. e560
|
article
|
| 50 |
Targeting PI3K/AKT pathway in triple-negative breast cancer
|
Delaloge, Suzette
|
|
2017
|
18 |
10 |
p. 1293-1294
|
article
|
| 51 |
Tax on tobacco and sugary drinks in the United Arab Emirates
|
Burki, Talha Khan
|
|
2017
|
18 |
10 |
p. e566
|
article
|
| 52 |
Thalidomide reduces chemotherapy-induced vomiting
|
Gourd, Elizabeth
|
|
2017
|
18 |
10 |
p. e570
|
article
|
| 53 |
The implementation of the Plan Esperanza and response to the imPACT Review
|
Vidaurre, Tatiana
|
|
2017
|
18 |
10 |
p. e595-e606
|
article
|
| 54 |
Use of cancer-related emergency departments
|
Burki, Talha Khan
|
|
2017
|
18 |
10 |
p. e568
|
article
|
Journal description